Clinical trials: Small Vessel Cerebrovascular Disease, active
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Multiple Sclerosis (MS), Cerebral Small Vessel Diseases
MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis
This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS).
- Trial name
- NCT07444047
- Where
- Norway
- Volunteers
- 1,000 people
- Sponsor
- Oslo University Hospital
Cerebral Small Vessel Disease
Intelligent Analysis and Clinical Validation of Cerebral Small Vessel Disease on Magnetic Resonance Imaging：A Multi-center Study
Cerebral small vessel disease (CSVD) accounts for 20% of ischemic strokes and is the most common cause of vascular cognitive impairment.
- Trial name
- NCT06667635
- Testing
- Artificial intelligence
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease
Prognosis of Cerebral Small Vessel Disease
Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation. The aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients…
- Conditions
- Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease, Cadasil, CAA - Cerebral Amyloid Angiopathy
- Trial name
- PRO-SVD (NCT05734378)
- Where
- Switzerland
- Volunteers
- 900 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Fabry Disease
Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI
This study will evaluate whether cardiac MRI T1 and T2 mapping improves our ability to detect early abnormalities in the heart in patients with Fabry disease and identify patients at increase risk of adverse events.
- Trial name
- FIESTA-MRI (NCT04856059)
- Testing
- Cardiac MRI, ECG/Holter and Blood Biomarkers
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- University Health Network, Toronto
Fabry Disease
Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry Disease
The goal of this observational study is to learn how enzyme replacement therapy works in patients with Fabry disease. The main question it aims to answer is: What medical problems do participants have? Participants already on…
- Trial name
- FAVORIT (NCT06880250)
- Where
- 23 sites in Russia
- Volunteers
- 100 people
- Sponsor
- NPO Petrovax
Fabry Disease
Novel Diagnostic and Prognostic Predictors in Fabry Cardiomyopathy: Proof of Concept in a Rare Disease
In this work, we address the understanding of the signaling pathways involved in cardiac remodeling in human SCD through molecular imaging analysis with a fibrosis marker.
- Trial name
- FABRyCar (NCT07351136)
- Testing
- PET scan of 68Ga-FAPI
- Volunteers
- 20 people
- Sponsor
- Núcleo de Apoio à Investigação Clínica - FMUP
Lacunar Stroke
The Relationship Between Controlling Risk Factors and Cerebral Haemodynamics in Lacunar Stroke
The goal of this observational study is to look at differences in brain blood flow before and after management of risk factors such as high blood pressure and diabetes in patients with lacunar stroke.
- Trial name
- LACUNAR_CA (NCT06354881)
- Testing
- Transcranial Doppler Ultrasonography (TCD) during sit-stand manoeuvres
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University of Leicester
Fabry Disease, Endothelial Dysfunction
Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a Prospective Observational Study
This study aims to gain a deeper understanding of endothelial dysfunction in patients with Fabry disease through a prospective study of the retinal microvasculature and to identify an objective, non-invasive marker to assess…
- Conditions
- Fabry Disease, Endothelial Dysfunction, Microvasculature
- Trial name
- VASCinFABRY (NCT06758648)
- Testing
- Dynamic retinal vessel analysis (DVA), Biochemistry and immune phenotyping, Questionnaires (Patient reported outcomes)
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Technical University of Munich
Cerebral Small Vessel Diseases, Stroke
Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD
The primary objectives of this trial are: 1. Efficacy evaluation of amlodipine folic acid tablets: To assess the effects of amlodipine folic acid tablets 5.8 mg (5 mg amlodipine + 0.8 mg folic acid)versus amlodipine tablets 5 mg…
- Trial name
- FAITH (NCT05169021)
- Testing
- Amlodipine folic acid 5.8mg+intensive antihypertensive therapy, Amlodipine folic acid 5.8mg+standard antihypertensive therapy, Amlodipine+intensive antihypertensive therapy
- Where
- China
- Volunteers
- 15,000 people
- Sponsor
- Beijing Tiantan Hospital
Fabry Disease
Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
Objective: To explore the safety and tolerability of different doses of EXG110 with Fabre disease
- Trial name
- NCT06539624
- Testing
- EXG110 injection
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Cerebral Small Vessel Diseases, Ischemic Stroke
A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
This study aims to construct a registry platform for microcirculatory disorders in a large sample of Chinese patients with cerebral small vessel disease and ischemic stroke; To explore the role of microcirculatory disorders in…
- Trial name
- MODEST (NCT06077305)
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Beijing Tiantan Hospital
Fabry Disease
Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease
Fabry disease (FD) is a genetic disorder that leads to progressive accumulation of fat or 'sphingolipid' within the tissues, including the heart muscle and conductive tissue.
- Trial name
- RaILRoAD (NCT03305250)
- Testing
- Implantable Loop Recorder
- Where
- 7 sites in Australia, United Kingdom
- Volunteers
- 169 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Systemic Lupus Erythematosus, Lupus Nephritis
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- BAH242 (NCT06350110)
- Testing
- CD19- BCMA CAR-T cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech
Ischemic Stroke
Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke
Along with the current clinical trial, the impact of adding atorvastatin or rosuvastatin in the first 24 hours on the clinical outcomes of first-ever small vessel stroke patients treated with clopidogrel and aspirin assessed…
- Trial name
- NCT06358313
- Testing
- Atorvastatin 40mg, Rosuvastatin 20mg
- Where
- Egypt
- Volunteers
- 600 people
- Sponsor
- Kafrelsheikh University
Fabry Disease, Fabry Disease, Cardiac Variant
Long-Term Follow-up of Subjects Who Were Treated With ST-920
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol.
- Trial name
- NCT05039866
- Testing
- ST-920
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 32 people
- Sponsor
- Sangamo Therapeutics
Stroke, Lacunar, Stroke, Acute Ischemic
Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)
The goal of this multicenter, double-blind, 2×2 factorial randomized controlled trial is to evaluate the efficacy and safety of isosorbide mononitrate, butylphthalide, and their combination in reducing disability in patients with…
- Conditions
- Stroke, Lacunar, Stroke, Acute Ischemic, Cerebral Small Vessel Diseases
- Trial name
- NCT07252544
- Testing
- Isosorbide Mononitrate, Butylphthalide
- Volunteers
- 3,156 people
- Sponsor
- Beijing Tiantan Hospital
Cerebral Small Vessel Disease
Neural Correlates (EEG and fMRI) of Gait in Small Vessel Disease
What is the purpose of this study? This observational study is being done to understand how cerebral small vessel disease (SVD) affects walking and balance.
- Trial name
- doesn't exist (NCT07372937)
- Testing
- No Intervention: Observational
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Fabry Disease
Anderson-Fabry Disease Fitness Improvement Training
This study will evaluate physical function, cardiorespiratory fitness, muscle strength, and quality of life in patients with Fabry disease and assess the effects of a 12-week physiotherapy-led exercise programme.
- Trial name
- A-FAD-FIT (NCT07495410)
- Testing
- Physiotherapy exercise programe
- Where
- Czechia
- Volunteers
- 50 people
- Sponsor
- General University Hospital, Prague
Fabry Disease
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-Gal A resulting from mutations affecting the GLA gene.
- Trial name
- NCT05698901
- Testing
- Agalsidase beta
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Mackay Memorial Hospital